- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00985712
A Study on the Effect of 2 Pen Devices on HbA1c
2 maj 2012 uppdaterad av: Eli Lilly and Company
A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults With Type 1 Diabetes: Novel Pen With Memory Function (HumaPen Memoir) vs. Conventional Pen Without Memory Function (HumaPen Luxura)
The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional HumaPen Luxura without memory function.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
263
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Aschaffenburg, Tyskland, 63739
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Asslar, Tyskland, 35614
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bad Mergentheim, Tyskland, 97980
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Berlin, Tyskland, 14089
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bosenheim, Tyskland, 55545
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Diez, Tyskland, 65582
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Dresden, Tyskland, 01307
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Erlangen, Tyskland, 91054
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Essen, Tyskland, 45355
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Falkensee, Tyskland, 14612
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Flensburg, Tyskland, D-24939
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Frankfurt, Tyskland, 60388
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Fulda, Tyskland, 36037
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Giessen, Tyskland, 35385
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hamburg, Tyskland, 21073
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hannover, Tyskland, 30173
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Herdecke, Tyskland, 58313
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Leipzig, Tyskland, 04103
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mainz, Tyskland, 55116
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Münster, Tyskland, 48153
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Neuwied, Tyskland, 56564
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Rehlingen-Siersburg, Tyskland, 66780
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Rotenburg-Fulda, Tyskland, 36199
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Saarbrücken, Tyskland, 66121
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Schkeuditz, Tyskland, 04435
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Schwedt/Oder, Tyskland, 16303
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tuebingen, Tyskland, 72076
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Warburg, Tyskland, 34414
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Wuppertal, Tyskland, 42283
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
8 år och äldre (Barn, Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Type 1 diabetes mellitus
- receiving at least 3 prandial injections per day with short-acting or analogue insulin
Exclusion Criteria:
- Insulin pump therapy
- receiving pre-mixed insulin preparations
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: HumaPen Luxura
Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
|
subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Andra namn:
subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Andra namn:
subcutaneously, daily for 24 weeks
|
Experimentell: HumaPen Memoir
Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
|
subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Andra namn:
subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Andra namn:
subcutaneously, daily for 24 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Endpoint
Tidsram: Baseline, Week 24
|
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
Least Squares (LS) Mean values were controlled for treatment, visit, treatment*visit interaction, screening HbA1c (≤9% / >9%), change of prandial insulin at baseline, and baseline HbA1c.
|
Baseline, Week 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Achieving Hemoglobin A1c (HbA1c) ≤7.5% and ≤7.0% at Week 24 Endpoint
Tidsram: Week 24
|
Week 24
|
|
Score in Insulin Delivery System Questionnaire (IDSQ) - Willingness to Continue at Week 24 Endpoint
Tidsram: Week 24
|
IDSQ is used to evaluate acceptance of study pen.
Willingness to continue was assessed by a single question, rated from 1 to 5 (1=Definitely unwilling and 5=Definitely willing).
Higher score indicates stronger desire to continue.
Least Squares (LS) Mean values were controlled for treatment and baseline score.
|
Week 24
|
30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes at Any Time From Baseline Through Week 24
Tidsram: Baseline through Week 24
|
Hypoglycemic episode is defined as blood glucose measurement ≤3.9 millimoles/Liter (mmol/L; 70 milligrams/deciliter [mg/dL]).
Adjusted rate = number of events in study period, divided by number of days in study period, then multiplied by 30.
|
Baseline through Week 24
|
30-Day Adjusted Rates of Self-Reported Hyperglycemic Episodes at Any Time From Baseline Through Week 24
Tidsram: Baseline through Week 24
|
Hyperglycemic episode is defined as blood glucose measurement >18 mmol/L (324 mg/dL).
Adjusted rate = number of events in study period, divided by number of days in study period, then multiplied by 30.
|
Baseline through Week 24
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST, Eli Lilly and Company
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2009
Primärt slutförande (Faktisk)
1 juli 2011
Avslutad studie (Faktisk)
1 juli 2011
Studieregistreringsdatum
Först inskickad
23 september 2009
Först inskickad som uppfyllde QC-kriterierna
25 september 2009
Första postat (Uppskatta)
28 september 2009
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
4 juni 2012
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
2 maj 2012
Senast verifierad
1 maj 2012
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 12704
- H9D-SB-ITAE (Annan identifierare: Eli Lilly and Company)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus, typ 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Diabetes typ 1 | Typ 1-diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinberoende | Ungdomsdiabetes | Diabetes, autoimmun | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | Diabetes mellitus, spröd | Diabetes mellitus, juvenil-debut och andra villkorFörenta staterna
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAvslutadTyp 1-diabetes mellitus | Diabetes mellitus, typ I | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | IDDMFörenta staterna, Australien
-
Capillary Biomedical, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Typ 1-diabetes mellitus | Diabetes mellitus, insulinberoende, 1Australien
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCAvslutadTyp 2-diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AvslutadTyp 1-diabetes mellitus | T1DM | T1D | Nyuppkommen typ 1-diabetes mellitusFörenta staterna, Australien
-
Spiden AGDCB Research AGRekryteringTyp 1-diabetes mellitus | Typ 1-diabetes mellitus med hypoglykemi | Typ 1-diabetes mellitus med hyperglykemiSchweiz
-
Shanghai Changzheng HospitalRekryteringSpröd typ 1-diabetes mellitusKina
-
Capillary Biomedical, Inc.AvslutadTyp 1-diabetes | Typ 1-diabetes mellitus | Diabetes mellitus, typ I | Diabetes mellitus, insulinberoende, 1 | IDDMÖsterrike
Kliniska prövningar på Insulin Lispro
-
Diasome PharmaceuticalsIntegriumAvslutadTyp 1-diabetes mellitusFörenta staterna
-
AdociaEli Lilly and CompanyAvslutadFriska deltagareSingapore
-
Inreda Diabetic B.V.Avslutad
-
SanofiAvslutad
-
Eli Lilly and CompanyAvslutadTyp 2-diabetes mellitusJapan, Korea, Republiken av, Kina, Kalkon
-
Diasome PharmaceuticalsIntegriumAvslutadDiabetes mellitus, typ 1Förenta staterna
-
AdociaEli Lilly and CompanyAvslutad
-
Chongqing Medical UniversityAvslutad
-
Eli Lilly and CompanyAvslutadDiabetes typ 1Förenta staterna, Spanien
-
Eli Lilly and CompanyAvslutadDiabetes mellitus, typ 2Kalkon, Argentina, Korea, Republiken av, Brasilien, Kina, Egypten, Indien, Spanien